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PATIENT SATISFACTION COMPARISONS BETWEEN PEDIATRICIANS 
AND OTHER PCPS: A MULTILEVEL CROSS-NATIONAL WEB BASED 
SURVEY STUDY
Chang J1, Patel I1, Feldman SR2, Balrkishnan R1
1University of Michigan at Ann Arbor, Ann Arbor, MI, USA, 2Wake Forest University School 
of Medicine, Winston Salem, NC, USA
OBJECTIVES: Very few studies have tried to evaluate comparative patient ratings of 
physician satisfaction across specialties. We examined the differences in physician 
satisfaction reported by patients accessing care from pediatricians versus other primary 
care physicians. METHODS: We conducted a cross sectional, national web based 
survey study consisting of anonymous patients who rated their physicians on the basis 
of treatment satisfaction that they received from their most recent outpatient visits. 
The survey was user friendly, validated and helped patients identify their physicians 
as per specialties and rate them on a scale of 0 (“not at all satisﬁed”) to 10 (“extremely 
satisﬁed”). The association of physician satisfaction between pediatricians and non-
pediatricians was assessed using hierarchical linear model (HLM). RESULTS: Using 
6982 patient survey responses, we matched 2724 PCP visits with a similar number of 
visits to pediatricians. After controlling other variables, pediatricians were associated 
with higher satisfaction, on average, than other PCPs (r03 = 14.79, p < 0.000). Spending 
time with patients was positively associated with patient satisfaction (r50 = 3.49, p < 
0.000) holding all other factors in the model constant. However, pediatricians were 
associated with lower time spent with patients (r53 = −1.1, p = 0.045). After controlling 
for other variables, waiting time was negatively associated with patient satisfaction 
(r40 = −0.37, p = 0.000). CONCLUSIONS: Our study ﬁnds that pediatricians are 
associated with higher patient satisfaction score than non-pediatricians. Increased time 
spent with the patient by pediatricians convinced to other PCPs to be the driver of 
the effect.
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THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D 
ELECTRONIC VERSION (EQ-5D EPRO)
Ashcroft-Jones AJ1, Furtado T1, Wild D2
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OBJECTIVES: The objective of this study was to produce translations of the ePRO 
version of the EQ-5D that are conceptually equivalent to the original and other lan-
guage versions, ensuring that the resulting translations are suitable for use in the ePRO 
format. METHODS: The methodology employed was: 1 forward and 1 back transla-
tion, review, developer review, linguistic validation interviews with 5 respondents (a 
mix of lay people and patients), second developer review and 2 proofreadings. 
RESULTS: The translation process highlighted numerous issues: 1) ‘Tap’, meaning to 
press lightly on the screen with a stylus, proved problematic in translation. In some 
languages, a literal translation would result in the patient touching the screen too 
lightly, not understanding that pressure was required. In other languages, there was 
no exact translation available. ‘press’ or ‘touch with the stylus’ were used as alterna-
tives (French and Russian respectively), ensuring that patients could navigate the 
platform; 2) In some Romance languages, the emphasis of ‘tap ONE box’, meaning 
only one, became lost due to the languages’ requirement of an article. Some translators 
used a capitalised deﬁnite article (‘THE’), others placed ‘ONLY ONE’ in brackets to 
provide the stress; 3) The Eastern European translators maintained that there is isno 
literal translation of ‘heading’, in the context of a title with sentences underneath. To 
render the intended meaning, they used ‘the text in bold’ or ‘in each of the groups’; 
4) Some languages found ‘Please do this by [. . .]’ a difﬁcult construction to translate 
directly and colloquially. The expression was substituted with ‘You do it by [. . .]’, 
which was more idiomatic. CONCLUSIONS: The EQ-5D ePRO has been translated 
and linguistically validated using a rigorous translation process. A number of cultural 
and linguistic issues became apparent and were resolved. The measure is now appro-
priate for use in multinational trials.
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SUPPLEMENTAL METHODOLOGY FOR TRANSLATING INSTRUMENTS 
DEVELOPED IN A LANGUAGE OTHER THAN ENGLISH
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OBJECTIVES: Procedures used to linguistically validate PROs are well documented 
for instruments originally developed in English. However, methodology concerning 
non-English based measures is largely uncharted. This paper outlines the challenges 
associated with translating PROs developed in a language other than English and 
recommends supplemental methodology for improving this process. METHODS: To 
establish guidelines for translating non-English PROs, several case studies of previous 
validations were performed. Techniques used to validate the Cancer Dyspnoea Scale 
(Japanese) were compared to those used for the Pain Detect Scale (German), DN4 
Questionnaire (French), and the Hôtel Dieu 16 (French). All questionnaires were 
translated from their source language into US English. The DN4 was subsequently 
translated into Dutch, while the CDS was translated into seven additional languages. 
Special attention was paid to maintaining conceptual equivalence, addressing collo-
quialisms native to the development setting and compensating for differing grammati-
cal rules. RESULTS: Linguistically validating non-English PROs poses numerous 
problems. Since most translators and project managers are English-based, an English 
adaptation of the instrument may need to be created prior to moving forward with 
other translations. Extreme care must be taken to accurately interpret all of the source 
instrument’s concepts. Recommended enhancements to the standard validation 
process include: assigning a project manager skilled in the source language to oversee 
all subsequent translations; creating a concept elaboration guide for both the original 
instrument and the English translation; conducting a specialized training session with 
translators to review the development of the original document and the English 
translation; placing extra emphasis on the meaning of colloquialisms and the formula-
tion of response sets. CONCLUSIONS: Linguistically validating PRO questionnaires 
developed in non-English settings presents special challenges. Evidence suggests that, 
in these situations, standard procedures may be insufﬁcient to produce conceptually 
equivalent translations acceptable for use in multinational clinical trials. In such cases, 
expanded procedures are recommended.
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ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF 
EPRO AND IVRS INSTRUMENTS
Gordon-Stables R, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: ePRO and IVRS PRO instruments are increasingly used in clinical 
trials. As a result translations of such instruments are also increasingly required. Whilst 
the approach recommended in the ISPOR translation task force paper (Wild et al. 
2005) should still be used, ePRO and IVRS instruments present some unique chal-
lenges during their translation and linguistic validation. This study seeks to clarify 
what some of those challenges are, and how to meet them. METHODOLOGY: 
Oxford Outcomes translation and linguistic validation projects involving ePRO/IVRS 
were reviewed to produce a list of tips on how best to localise such instruments. 
RESULTS: Give translators information about limited screen size up front to avoid 
shortening strings later in the process. Participants in IVRS studies have to listen to 
the PRO instrument; therefore prompts should not be too long and have too many 
concepts (this helps both translators and participants). Avoid concatenation (where a 
sentence is split in the software coding and put back together at run time). Don’t split 
question stems from the questions. Provide translators with existing translations lever-
aged from previous translation projects to ensure consistency. Ideally cognitive debrief-
ing of the translation should be carried out via the medium of ﬁnal delivery (e.g. if it 
is on a handheld computer, the participants see the instrument on a handheld com-
puter). It is worth having a linguist check ﬁnal translated software/listen to recorded 
prompts—to ensure no errors have been introduced at software building / recording 
stage. CONCLUSIONS: With some forward planning, the challenges of translating 
and validating an ePRO or IVRS instrument can be met, ensuring a translation that 
is conceptually equivalent and suitable for use in the target country with the target 
patient population.
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VALIDITY OF SELF-REPORT WITH RESPECT TO PRESCRIPTION 
MEDICATIONS AMONG PREGNANT WOMEN
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OBJECTIVES: Accuracy of self-report regarding prescription medication use among 
pregnant women is largely unknown. Accurate self-reported information is needed for 
medication reconciliation purposes, clinical management, clinical teratology research, 
and monitoring of adherence. This study examines the accuracy of self-reported medi-
cation use by pregnant women for medications used chronically and episodically or 
intermittently during pregnancy. METHODS: This was a cross-sectional analysis of 
data collected through the University of New Mexico (UNM) cohort study, “Safety 
of Medication and Perception of Teratogenicity” (SMART). Pregnant women were 
recruited from UNM prenatal care clinics and were asked to report all medications 
they took since their last menstrual period. The analysis was limited to women enrolled 
in the ﬁrst year of the study who had at least one prescription for diabetes or opioid 
analgesics medications (representative of chronic and acute medication use, respec-
tively). The accuracy of agreement between self-report and medical records for each 
medication class was estimated by simple (κ) and prevalence and bias adjusted 
(PABAK) kappa. Information from the medical records was used as the ‘gold-stan-
dard’. RESULTS: A total of 92 pregnant women were included in the analysis. Agree-
ment for diabetes medications was near perfect (κ = 0.87; PABAK = 0.91); whereas 
poor-to-moderate concordance was observed for opioid analgesics (κ = 0.29; PABAK 
= 0.57). Among antidiabetic medications, concordance was highest for biguanides (κ 
= 0.90; PABAK = 0.93) and lowest for sulfonylureas (κ = 0.83; PABAK = 0.87); 
whereas among opioid analgesics, highest agreement was observed for strong agonists 
(κ = 0.51; PABAK = 0.56) and lowest for moderate/low agonists (κ = 0.06; PABAK 
= 0.59). CONCLUSIONS: This study suggests poor accuracy of self-report with 
respect to prescription medications used as short courses or intermittently during 
pregnancy. Therefore, in clinical studies assessing safety of such medications in preg-
nancy, self-reported information needs to be supplemented by other sources. Accuracy 
of self-report for medications used chronically is acceptable.
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PATIENT REPORTED OUTCOME RECALL PERIODS IN LIGHT OF  
THE FINAL FDA GUIDANCE
Wild D, Nixon A
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The selection of the most appropriate recall periods for PROs has been 
a topic of much debate since the release of the draft FDA PRO guidance in February 
2006. The ﬁnal PRO guidance (December 2009) provides more insight into the way 
